Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial. (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1097/hc9.0000000000000057
PubMed Identifier: 36809195
Publication URI: http://europepmc.org/abstract/MED/36809195
Type: Journal Article/Review
Volume: 7
Parent Publication: Hepatology communications
Issue: 3
ISSN: 2471-254X